Quale sarebbe il prezzo per Impel Pharmaceuticals Inc. (IMPL)

Il prezzo per Impel Pharmaceuticals Inc. (IMPL) è $0.1011

Qual è la capitalizzazione di mercato per Impel Pharmaceuticals Inc. (IMPL)

La capitalizzazione di mercato per Impel Pharmaceuticals Inc. (IMPL) è $1.96M

Impel Pharmaceuticals Inc. (IMPL) Rapporto P/B

Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical firm, concentrating its efforts on creating and commercializing therapies for individuals in the United States who are affected by central nervous system (CNS) conditions. Leading its product portfolio is Trudhesa, an innovative upper nasal formulation of dihydroergotamine, specifically engineered for the prompt relief of acute migraine attacks. Furthermore, the company's development pipeline encompasses INP105, another upper nasal medication containing olanzapine, currently being advanced for the rapid treatment of agitation and aggressive behaviors associated with autism spectrum disorder. Impel is also progressing with INP107, an intranasal carbidopa/levodopa compound, which has already successfully concluded its Phase IIa clinical trial aimed at managing "OFF" episodes in Parkinson's disease patients. Initially established in 2008, the company was formerly known as Impel NeuroPharma, Inc. before rebranding to Impel Pharmaceuticals Inc. in April 2022. Its corporate headquarters are situated in Seattle, Washington.

Anno	Rapporto P/B	Cambia
Non abbastanza dati per le date fornite.

Anno

Rapporto P/B

Cambia

Non abbastanza dati per le date fornite.

Azienda	Rapporto P/B	Differenza del rapporto P/B	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	3.4612	-	BE

Azienda

Rapporto P/B

Differenza del rapporto P/B

Il paese